LUTATHERA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(14 years from now) | |
| US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(14 years from now) | |
Lutathera is owned by Aaa Usa Inc.
Lutathera contains Lutetium Lu 177 Dotatate.
Lutathera has a total of 2 drug patents out of which 0 drug patents have expired.
Lutathera was authorised for market use on 26 January, 2018.
Lutathera is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Lutathera from 26 January, 2022.
The generics of Lutathera are possible to be released after 25 July, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-166) | Jan 26, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 26, 2023 |
Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient
NCE-1 date: 26 January, 2022
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
LUTATHERA family patents
